211 related articles for article (PubMed ID: 26497918)
1. Clinical Factors Associated With a Short Survival Time After Percutaneous Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated Model.
Alawneh A; Tuqan W; Innabi A; Al-Nimer Y; Azzouqah O; Rimawi D; Taqash A; Elkhatib M; Klepstad P
J Pain Symptom Manage; 2016 Feb; 51(2):255-61. PubMed ID: 26497918
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in malignant ureteric obstruction.
Lienert A; Ing A; Mark S
BJU Int; 2009 Oct; 104(7):938-41. PubMed ID: 19338533
[TBL] [Abstract][Full Text] [Related]
3. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases.
Ishioka J; Kageyama Y; Inoue M; Higashi Y; Kihara K
J Urol; 2008 Aug; 180(2):618-21; discussion 621. PubMed ID: 18554655
[TBL] [Abstract][Full Text] [Related]
4. A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients.
Cordeiro MD; Coelho RF; Chade DC; Pessoa RR; Chaib MS; Colombo-Júnior JR; Pontes-Júnior J; Guglielmetti GB; Srougi M
BJU Int; 2016 Feb; 117(2):266-71. PubMed ID: 25327474
[TBL] [Abstract][Full Text] [Related]
5. Ureteric stents vs percutaneous nephrostomy for initial urinary drainage in children with obstructive anuria and acute renal failure due to ureteric calculi: a prospective, randomised study.
ElSheemy MS; Shouman AM; Shoukry AI; ElShenoufy A; Aboulela W; Daw K; Hussein AA; Morsi HA; Badawy H
BJU Int; 2015 Mar; 115(3):473-9. PubMed ID: 24698195
[TBL] [Abstract][Full Text] [Related]
6. The role of percutaneous nephrostomy in malignant ureteric obstruction.
Wilson JR; Urwin GH; Stower MJ
Ann R Coll Surg Engl; 2005 Jan; 87(1):21-4. PubMed ID: 15720902
[TBL] [Abstract][Full Text] [Related]
7. Use of nephrostomy tubes in ureteric obstruction from incurable malignancy.
Little B; Ho KJ; Gawley S; Young M
Int J Clin Pract; 2003 Apr; 57(3):180-1. PubMed ID: 12723719
[TBL] [Abstract][Full Text] [Related]
8. Prognostic marker for patients with malignant ureter obstruction.
Azuma T; Nagase Y; Oshi M
Clin Genitourin Cancer; 2013 Sep; 11(3):353-6. PubMed ID: 23787166
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right?
Misra S; Coker C; Richenberg J
Int Urol Nephrol; 2013 Jun; 45(3):627-32. PubMed ID: 23666587
[TBL] [Abstract][Full Text] [Related]
10. Role of percutaneous nephrostomy (PCN) in malignant ureteral obstruction.
Jalbani MH; Deenari RA; Dholia KR; Oad AK; Arbani IA
J Pak Med Assoc; 2010 Apr; 60(4):280-3. PubMed ID: 20419970
[TBL] [Abstract][Full Text] [Related]
11. Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer.
Nariculam J; Murphy DG; Jenner C; Sellars N; Gwyther S; Gordon SG; Swinn MJ
Br J Radiol; 2009 Jul; 82(979):571-6. PubMed ID: 19153185
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences?
Ku JH; Lee SW; Jeon HG; Kim HH; Oh SJ
Urology; 2004 Nov; 64(5):895-9. PubMed ID: 15533473
[TBL] [Abstract][Full Text] [Related]
13. Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy.
Radecka E; Magnusson M; Magnusson A
Acta Radiol; 2006 Apr; 47(3):328-31. PubMed ID: 16613316
[TBL] [Abstract][Full Text] [Related]
14. Malignant ureteral obstruction: outcomes after intervention. Have things changed?
Wong LM; Cleeve LK; Milner AD; Pitman AG
J Urol; 2007 Jul; 178(1):178-83; discussion 183. PubMed ID: 17499300
[TBL] [Abstract][Full Text] [Related]
15. Palliative urinary diversion in patients with malignant ureteric obstruction due to gynaecological cancer.
Perri T; Meller E; Ben-Baruch G; Inbar Y; Apter S; Heyman L; Dotan Z; Korach J
BMJ Support Palliat Care; 2022 Dec; 12(e6):e855-e861. PubMed ID: 31018967
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for overall survival in malignant ureteral obstruction.
Mason JB; Creswell M; Egan J; Dall C; Sholklapper T; Galloway LA; Orzel J; Lee H; Desale S; Stamatakis L
Can J Urol; 2022 Jun; 29(3):11162-11169. PubMed ID: 35691038
[TBL] [Abstract][Full Text] [Related]
17. Development of prognostic model for predicting survival after retrograde placement of ureteral stent in advanced gastrointestinal cancer patients and its evaluation by decision curve analysis.
Kawano S; Komai Y; Ishioka J; Sakai Y; Fuse N; Ito M; Kihara K; Saito N
Minerva Urol Nefrol; 2016 Oct; 68(5):437-43. PubMed ID: 26554732
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of locally advanced cervical cancer presenting with obstructive uropathy: An institutional audit.
Salunkhe R; Chopra S; Kulkarni S; Shetty N; Engineer R; Mahantshetty U; Ghosh J; Gupta S; Shrivastava SK
Indian J Cancer; 2020; 57(4):416-422. PubMed ID: 33078748
[TBL] [Abstract][Full Text] [Related]
19. Use of percutaneous nephrostomy in malignant ureteric obstruction.
Chapman ME; Reid JH
Br J Radiol; 1991 Apr; 64(760):318-20. PubMed ID: 2025771
[TBL] [Abstract][Full Text] [Related]
20. The role of percutaneous nephrostomy in malignant urinary tract obstruction.
Watkinson AF; A'Hern RP; Jones A; King DM; Moskovic EC
Clin Radiol; 1993 Jan; 47(1):32-5. PubMed ID: 8428414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
